Sonablate Corp. specializes in High-Intensity Focused Ultrasound (HIFU) technology, specifically designed for the treatment of non-metastatic prostate cancer. The Sonablate HIFU system offers a non-invasive alternative to traditional treatments such as surgery and radiation, providing a customizable focal therapy option that prioritizes optimal patient outcomes. The technology is distinguished by its real-time ultrasound feedback, which allows physicians to visualize the procedure as it unfolds, enhancing precision and control during treatment. Additionally, Sonablate HIFU incorporates multiple patient safety features, including Tissue Change Monitoring and Reflexivity Index Monitoring, ensuring that physicians can monitor the procedure's safety and efficacy in real-time.

Recent clinical studies have demonstrated the effectiveness of Sonablate HIFU in achieving good disease control for patients with clinically significant prostate cancer. Notably, a multi-institute study involving 1,379 men showed promising medium-term outcomes, with high rates of metastasis-free survival and failure-free survival in both intermediate and high-risk cancer patients. Furthermore, patient satisfaction with the focal therapy approach has been reported to be high, with low rates of treatment regret compared to conventional therapies. This evidence underscores the potential of Sonablate HIFU as a viable option for patients seeking effective and less invasive treatment for prostate cancer.

United States

Our mission is to provide the next generation of sound medicine through proven ablative technologies that precisely deliver care while sparing healthy tissue. This next generation of care involves expanding our current HIFU technologies to treat a range of urological indications that balance treatment effectiveness and quality of life.

Sonablate Corp.

Company Details